XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Strategic Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Jan. 31, 2020
Dec. 31, 2019
Nov. 30, 2019
Apr. 30, 2018
Feb. 28, 2018
Mar. 31, 2017
Mar. 31, 2022
Sep. 30, 2021
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
License fee                 $ 25,000   $ 25,000    
Accrued expenses                 3,537,856     $ 3,136,244  
Payment of additional consideration                 46,500,000        
Microchips Biotech, Inc.                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Asset acquisition, contingent consideration                         $ 50,000
Common stock issued to microchips capital stock holders (in shares) 700,000                        
Business acquisition transaction value         $ 2,400,000                
Business combination shares issued (in usd per share)         $ 0.79                
Cash and cash equivalents         $ 6,100,000                
Contingent consideration, liability         3,500,000                
Current portion of contingent consideration   $ 1,000,000     1,000,000                
Potential additional consideration payable   1,250,000                      
Accrued expenses                 250,000     250,000  
Cash paid to stockholders' representative $ 75,000                        
Payment of additional consideration   $ 1,250,000                      
Microchips Biotech, Inc. | Upon Achievement of Specified Development and Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payments         46,500,000                
Current portion of contingent consideration         55,000,000                
Microchips Biotech, Inc. | Research and development                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Business acquisition transaction value         $ 202,000                
Microchips Biotech, Inc. | Common stock                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Common stock issued to microchips capital stock holders (in shares)         3,000,000                
ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payments               $ 2,500,000          
Maximum | ADVA Tec Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Percentage of royalty rate               10.00%          
Maximum | ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payments               $ 14,600,000          
Minimum | ADVA Tec Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Percentage of royalty rate               1.00%          
MilanaPharm | Upon Achievement of Specified Development and Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock                 $ 50,000,000        
Bayer Healthcare License Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock     $ 310,000,000                    
Upfront license fee paid     1,000,000                    
Revenue from grant for notice of award     $ 20,000,000                    
Initial term of license agreement     15 years                    
Licensing Agreements | ADVA Tec Agreement | Upon Reaching Certain Worldwide Net Sales Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payments term               3 years          
Milestone payments               $ 20,000,000          
Licensing Agreements | MilanaPharm                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock                     $ 1,000,000 250,000  
License fee       $ 235,000                  
License fee to be paid upon contingency                         110,000
Royalty agreement term                 10 years        
License agreement termination periodic discontinued sale of product       60 days                  
License agreement termination period due to performance failure       120 days                  
Certain clinical and regulatory development milestone payments       90 days                  
Licensing Agreements | MilanaPharm | Upon Achieving Certain Development Milestones | Maximum                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock       $ 300,000                  
Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock                       750,000 100,000
Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones | Upon Achievement of Specified Development and Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock                       $ 200,000  
Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones | Maximum                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock                 $ 500,000        
Licensing Agreements | MilanaPharm | Licensed Product or Process for Vaginal or Urological Use                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock                 250,000        
Assignment Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
License fee       512,500                  
Assignment Agreement | Hammock Pharmaceuticals, Inc                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
License fee to be paid upon contingency                         $ 137,500
Assignment Agreement | Hammock Pharmaceuticals, Inc | Upon Achieving Certain Clinical and Regulatory Development Milestones | Maximum                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock       $ 1,100,000                  
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Percentage of rights to inventions by employees under license agreement             50.00%            
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Maximum                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock             $ 18,000,000            
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Minimum                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock             500,000            
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Upon Achieving Certain Commercial Milestones | Maximum                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock             100,000,000            
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Upon Achieving Certain Commercial Milestones | Minimum                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock             $ 10,000,000            
Juniper Pharmaceuticals, Inc                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront license fee paid           $ 250,000              
Potential annual license maintenance fee, payments in year one           50,000              
Potential annual license maintenance fee payments, thereafter           100,000              
Juniper Pharmaceuticals, Inc | Clinical and Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Maximum potential milestone payments           13,500,000              
Juniper Pharmaceuticals, Inc | Sales Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Maximum potential milestone payments           $ 30,300,000              
Organon                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront license fee paid                 10,000,000        
Milestone payment paid in common stock                 182,500,000        
First commercial sale amount                 2,500,000        
Sales based milestones amount                 $ 180,000,000        
Milestone payments term                 10 years        
Catalent and MilanaPharm                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Annual maintenance fee                   $ 100,000      
Net amount payable                 $ 900,000        
Catalent and MilanaPharm | Licensing Agreements                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment paid in common stock                   $ 1,000,000